Amniotic fluid embolism: The pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction

© 2020 S.O.G. CANADA Inc.. All rights reserved. Objective: This article aims to review and provide more understanding of current knowledge of amniotic fluid embolism regarding pathophysiology, diagnostic criteria, risk factors, indicating biomarkers, treatment strategies and outcomes of some case re...

Full description

Saved in:
Bibliographic Details
Main Authors: R. Suvannasarn, T. Tongsong, P. Jatavan
Format: Journal
Published: 2020
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089842966&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/70871
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-70871
record_format dspace
spelling th-cmuir.6653943832-708712020-10-14T08:42:59Z Amniotic fluid embolism: The pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction R. Suvannasarn T. Tongsong P. Jatavan Medicine © 2020 S.O.G. CANADA Inc.. All rights reserved. Objective: This article aims to review and provide more understanding of current knowledge of amniotic fluid embolism regarding pathophysiology, diagnostic criteria, risk factors, indicating biomarkers, treatment strategies and outcomes of some case reports. Study design: A systematic literature review was performed using the PubMed database, restricted to articles published in English from 1992 to 2018. Original research, case reports, guideline recommendations, and review articles were reviewed in this study. Summary: Amniotic fluid embolism (AFE) is a rare catastrophic obstetric condition defined by clinical manifestations of pregnancy with sudden onset of cardiopulmonary arrest, consumptive coagulopathy or neurological deficits without other explainable illnesses. The incidence varies from 1.7-14.8 cases per 100,000 worldwide. The current understanding of AFE pathophysiology includes fetal components obstructing maternal microvessels with subsequent anaphylactoid reaction. Maternal pulmonary vasospasm and hematologic activation occur later, followed by heart failure and sudden cardiovascular collapse. Some of the possible risk factors for AFE include; 1) Maternal risk: Age over 35 years, hypertensive disorder and diabetes mellitus; 2) Fetal risk: polyhydramnios, multiparity, non-vertex at delivery, fetal distress and fetal macrosomia; 3) Obstetric risks: Amniocentesis, artificial amniotic fluid injection, oxytocin infusion, and placental abruption. Some of the useful biomarkers have been proposed including zinc coproporphyrin-1, squamous cell carcinoma antigen, carcinoembryonic antigen, cancer antigen 125, Siatyl Tn, monoclonal antibody TKH-2, C3, C4, tryptase, insulin-like growth factor binding protein-1, C1 esterase inhibitor. Management of AFE requires immediate basic life support and advanced cardiac life support. Adequate oxygenation, ventilation, coagulopathy correction, and appropriate vasopressors are recommended. However, the outcome prediction of AFE remains challenging. 2020-10-14T08:42:59Z 2020-10-14T08:42:59Z 2020-04-15 Journal 03906663 2-s2.0-85089842966 10.31083/j.ceog.2020.02.5176 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089842966&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70871
institution Chiang Mai University
building Chiang Mai University Library
continent Asia
country Thailand
Thailand
content_provider Chiang Mai University Library
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
R. Suvannasarn
T. Tongsong
P. Jatavan
Amniotic fluid embolism: The pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction
description © 2020 S.O.G. CANADA Inc.. All rights reserved. Objective: This article aims to review and provide more understanding of current knowledge of amniotic fluid embolism regarding pathophysiology, diagnostic criteria, risk factors, indicating biomarkers, treatment strategies and outcomes of some case reports. Study design: A systematic literature review was performed using the PubMed database, restricted to articles published in English from 1992 to 2018. Original research, case reports, guideline recommendations, and review articles were reviewed in this study. Summary: Amniotic fluid embolism (AFE) is a rare catastrophic obstetric condition defined by clinical manifestations of pregnancy with sudden onset of cardiopulmonary arrest, consumptive coagulopathy or neurological deficits without other explainable illnesses. The incidence varies from 1.7-14.8 cases per 100,000 worldwide. The current understanding of AFE pathophysiology includes fetal components obstructing maternal microvessels with subsequent anaphylactoid reaction. Maternal pulmonary vasospasm and hematologic activation occur later, followed by heart failure and sudden cardiovascular collapse. Some of the possible risk factors for AFE include; 1) Maternal risk: Age over 35 years, hypertensive disorder and diabetes mellitus; 2) Fetal risk: polyhydramnios, multiparity, non-vertex at delivery, fetal distress and fetal macrosomia; 3) Obstetric risks: Amniocentesis, artificial amniotic fluid injection, oxytocin infusion, and placental abruption. Some of the useful biomarkers have been proposed including zinc coproporphyrin-1, squamous cell carcinoma antigen, carcinoembryonic antigen, cancer antigen 125, Siatyl Tn, monoclonal antibody TKH-2, C3, C4, tryptase, insulin-like growth factor binding protein-1, C1 esterase inhibitor. Management of AFE requires immediate basic life support and advanced cardiac life support. Adequate oxygenation, ventilation, coagulopathy correction, and appropriate vasopressors are recommended. However, the outcome prediction of AFE remains challenging.
format Journal
author R. Suvannasarn
T. Tongsong
P. Jatavan
author_facet R. Suvannasarn
T. Tongsong
P. Jatavan
author_sort R. Suvannasarn
title Amniotic fluid embolism: The pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction
title_short Amniotic fluid embolism: The pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction
title_full Amniotic fluid embolism: The pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction
title_fullStr Amniotic fluid embolism: The pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction
title_full_unstemmed Amniotic fluid embolism: The pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction
title_sort amniotic fluid embolism: the pathophysiology, diagnostic clue, and blood biomarkers indicator for disease prediction
publishDate 2020
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089842966&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/70871
_version_ 1681752981721055232